文献速递心脑血管急症消化、代谢与肾脏急症

验证HERDOO2规则指导女性无诱因静脉血栓形成治疗时长:跨国前瞻性队列管理研究

Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study.
PubMed 文献 · BMJ · 2017-03-17
一句话结论女性首次无诱因静脉血栓栓塞症完成短期抗凝后,HERDOO2评分0或1分者停药后1年复发风险低(每年3.0%),可安全停药。

该研究为跨国前瞻性队列管理研究,在7个国家44个二级或三级中心纳入2785例完成5-12个月短期抗凝的首次无诱因静脉血栓栓塞症患者,验证HERDOO2规则。1213例女性中631例(51.3%)评为低危(HERDOO2标准0或1项)并停药,591例实际停药,随访1年复发VTE为每患者年3.0%(95%CI 1.8%-4.8%)。高危女性及男性停药者复发率为每患者年8.1%(95%CI 5.2%-11.9%),继续抗凝者为每患者年1.6%(95%CI 1.1%-2.3%)。结论认为低危女性完成短期治疗后可以安全停用抗凝药。

要点

  • HERDOO2低危定义为女性首次无诱因VTE完成5-12个月抗凝后,满足0或1项标准(色素沉着、水肿或红斑;D-二聚体≥250 μg/L;BMI≥30;年龄≥65岁)。
  • 631例低危女性中591例停药,随访1年复发VTE为每患者年3.0%(95%CI 1.8%-4.8%),支持可安全停药。
  • 高危女性(≥2项HERDOO2标准)及男性停药者复发VTE为每患者年8.1%(95%CI 5.2%-11.9%),继续抗凝者为每患者年3.0%(95%CI 1.8%-4.8%)对照的每患者年1.6%(95%CI 1.1%-2.3%)。
  • 研究纳入2785例完成短期抗凝的首次无诱因VTE患者,失访率2.3%,主要终点为独立盲法判定的1年内症状性复发VTE。
  • 该规则不适用于男性及高危女性(≥2项标准),其抗凝管理由临床医生和患者决定。

适用人群与场景

  • 首次无诱因静脉血栓栓塞症(近端下肢深静脉血栓或肺栓塞)且已完成5-12个月短期抗凝治疗的患者。
  • 研究纳入女性1213例,男性及高危女性纳入观察组;排除拒绝参与者370例。
  • 适用场景为二级或三级中心门诊抗凝管理,非急诊或ICU床旁急性期决策。

诊断标准与关键阈值

  • HERDOO2规则标准:色素沉着、水肿或红斑(任一下肢);D-二聚体≥250 μg/L;肥胖(BMI≥30);年龄≥65岁。
  • 女性满足0或1项标准为低危,可停用抗凝药;满足≥2项为高危。
  • 男性不适用该规则,抗凝管理由临床医生和患者决定。

处置流程与药物剂量

  • 女性首次无诱因VTE完成5-12个月短期抗凝后,评估HERDOO2标准。
  • 0或1项标准者为低危,可停用口服抗凝药。
  • ≥2项标准的高危女性及男性,抗凝管理由临床医生和患者决定(观察组)。

研究设计与关键结果

  • 研究类型:跨国前瞻性队列管理研究,7个国家44个中心,纳入2785例完成5-12个月短期抗凝的首次无诱因VTE患者,失访2.3%。
  • 1213例女性中631例(51.3%)为低危,591例停药;随访564患者年,17例复发VTE,每患者年3.0%(95%CI 1.8%-4.8%)。
  • 323例高危女性及男性停药者随访309患者年,25例复发VTE,每患者年8.1%(95%CI 5.2%-11.9%)。
  • 1802例高危女性及男性继续抗凝者随访1758患者年,28例复发VTE,每患者年1.6%(95%CI 1.1%-2.3%)。
  • 主要终点为独立盲法判定的1年内症状性复发VTE。

证据类型、等级与局限

  • 证据类型:前瞻性队列管理研究(验证性研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对完成5-12个月抗凝的首次无诱因VTE女性,可用HERDOO2规则识别低危者(0或1项标准)并考虑停药。
  • 该规则不适用于男性及HERDOO2≥2项的高危女性,其抗凝决策需个体化。
  • 低危女性停药后1年复发VTE为每患者年3.0%,需在随访中监测症状复发。

指南或共识出处

  • HERDOO2规则验证研究,发表于BMJ,临床试验注册号NCT00967304。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Objective To prospectively validate the HERDOO2 rule (Hyperpigmentation, Edema, or Redness in either leg; D-dimer level ≥250 μg/L; Obesity with body mass index ≥30; or Older age, ≥65 years), which states that women with none or one of the criteria can safely discontinue anticoagulants after short term treatment.Design Prospective cohort management study.Setting 44 secondary or tertiary care centres in seven countries.Participants Of 3155 consecutive eligible participants with a first unprovoked venous thromboembolism (VTE, proximal leg deep vein thrombosis or pulmonary embolism) who completed 5-12 months of short term anticoagulant treatment, 370 declined to participate, leaving 2785 enrolled participants. 2.3% were lost to follow-up.Interventions Women with none or one of the HERDOO2 criteria were classified as at low risk of recurrent VTE and discontinued anticoagulants (intervention arm), whereas anticoagulant management for high risk women (≥2 HERDOO2 criteria) and men was left to the discretion of the clinicians and patients (observation arm).Main outcome measure Recurrent symptomatic VTE (independently and blindly adjudicated) over one year of follow-up.Results Of 1213 women, 631 (51.3%) were classified as low risk and 591 discontinued oral anticoagulant treatment. In the primary analysis, 17 low risk women who discontinued anticoagulants developed recurrent VTE during 564 patient years of follow-up (3.0% per patient year, 95% confidence interval 1.8% to 4.8%). In 323 high risk women and men who discontinued anticoagulants, 25 had VTE during 309 patient years of follow-up (8.1%, 5.2% to 11.9%), whereas in 1802 high risk women and men who continued anticoagulants 28 had recurrent VTE during 1758 patient years of follow-up (1.6%, 1.1% to 2.3%).Conclusions Women with a first unprovoked VTE event and none or one of the HERDOO2 criteria have a low risk of recurrent VTE and can safely discontinue anticoagulants after completing short term treatment.Trial registration clinicaltrials.gov NCT00967304.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Rodger MA, Le Gal G, Anderson DR, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017. PMID: 28314711. doi:10.1136/bmj.j1065

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。